Age-related Macular Degeneration (AMD) Integrative Biology Initiative

Age-related Macular Degeneration (AMD) Integrative Biology Initiative is sponsored by National Eye Institute (NEI). Aims to support studies using patient-derived induced pluripotent stem cell (iPSC) lines to discover the underlying pathophysiology of AMD.

A **. gov** website belongs to an official government organization in the United States.

* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.

gov Maintenance Calendar Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-EY-21-002 Funding Opportunity Title:Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Category of Funding Activity:Health Expected Number of Awards: Assistance Listings:93.

867 -- Vision Research Cost Sharing or Matching Requirement:No Last Updated Date:Nov 17, 2021 Original Closing Date for Applications:Feb 17, 2022 Current Closing Date for Applications:Feb 17, 2022 Archive Date:Mar 25, 2022 Estimated Total Program Funding: Eligible Applicants:City or township governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Private institutions of higher education Special district governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## Additional Information Agency Name:National Institutes of Health Description:This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative.

This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2).

The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects. Link to Additional Information:http://grants.

nih. gov/grants/guide/rfa-files/RFA-EY-21-002. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: OERWebmaster03@od.

nih. gov See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

#### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.

Unsaved changes will be lost.